Study directory

Schizophrenia studies

Compare studies and check their requirements with the research team.

Back to overview
More filters: keywords, city, remote
4306studies shown
Showing 3,433-3,444 of 4,306
Drug study icon
TerminatedEUCTR 2010-020470-42

A Phase III, multi-center, randomized, 24 week, double-blind, parallel-group, placebo-controlled study to evaluate efficacy and safety of RO4917838 in stable patients with persistent, predominant n...

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In Bulgaria
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrugA study involving a medication or substance.
Countries
Bulgaria, Czechia, Italy
Sponsor
F. Hoffmann-La Roche Ltd
Condition
Schizophrenia
Drug study icon
CompletedEUCTR 2010-020579-21

A Phase IV Prospective, Double-blind, Double-dummy, Randomised, Crossover Study to Assess the Impact on Daily Cognitive Functioning of Quetiapine Fumarate Immediate Release (Seroquel IR®) Dosed twi...

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In Austria
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrug
Countries
Austria, Denmark, Germany, ...
Sponsor
AstraZeneca AB
Condition
Schizophrenia
Drug study icon
CompletedEUCTR 2015-003331-36

A Phase IV, Open-label, Non-randomized, Clinical Trial to Evaluate the Safety of self-administered ADASUVE(R) (Staccato loxapine for inhalation) in Agitated Patients outside the hospital setting

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In Austria
Why is this study shown?

This study is directly about Schizophrenia.

Schizophrenia, BipolarityDrug
Countries
Austria, Norway
Sponsor
FERRER INTERNACIONAL SA
Condition
Schizophrenia, Bipolarity
Drug study icon
CompletedEUCTR 2007-005773-63

A Pilot Study of Three-Weeks, Randomized, Prospective, Open Comparison in Schizophrenic In-patients Treated with Quetiapine Prolong or Oral Risperidone at Flexible Dose

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In Finland
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrug
Countries
Finland
Sponsor
AstraZeneca Oy
Condition
Schizophrenia
Drug study icon
CompletedEUCTR 2020-000437-41

A pilot, open-label, rater-blinded, randomized, parallel-group, multi-center study to evaluate the safety, tolerability and preliminary efficacy of three add-on fixed doses of Evenamide in patients...

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In Italy
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrug
Countries
Italy
Sponsor
NEWRON PHARMACEUTICALS SPA
Condition
Schizophrenia
Drug study icon
CompletedEUCTR 2006-006184-23

A randomised, double-blind, placebo- and olanzapine- controlled, parallel-group study to evaluate the efficacy and safety of 3 fixed doses of S 33138 in treatment of patients with an acute episode ...

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In Slovakia
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrug
Countries
Slovakia
Sponsor
Institut de Recherches Internationales Servier
Condition
Schizophrenia
Drug study icon
CompletedEUCTR 2006-003560-62

A Randomized, Double-Blind, Parallel-Group, Comparative Study of Flexible Doses of Paliperidone Palmitate and Flexible Doses of Risperidone Long-Acting Intramuscular Injection in Subjects with Schi...

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In Austria
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrug
Countries
France, Austria, Bulgaria, ...
Sponsor
Janssen-Cilag International N.V.
Condition
Schizophrenia
Drug study icon
TerminatedEUCTR 2017-001084-20

A Randomized, Double-Blind, Placebo Controlled, Two-Period Cross-Over, Proof of Activity Study to Evaluate the Effects of TAK-041 on Motivational Anhedonia as Add-On to Antipsychotics in Subjects W...

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In United Kingdom
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrug
Countries
United Kingdom
Sponsor
Takeda Development Centre Europe Ltd.
Condition
Schizophrenia
Drug study icon
CompletedEUCTR 2006-006434-17

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose Response Study to Evaluate the Efficacy and Safety of 3 Fixed Doses (25 mg eq., 100 mg eq., and 150 mg eq.) of Paliperidone Palm...

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In Romania
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrug
Countries
Romania
Sponsor
Janssen-Cilag International N.V.
Condition
Schizophrenia
Drug study icon
CompletedEUCTR 2012-003209-92

A Randomized, Double-blind, Placebo-controlled, Parallel, 26 Week, Phase 3 Study of 2 Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo as an Adjunctive Pro-cogniti...

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In Italy
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrug
Countries
United Kingdom, Italy, Poland
Sponsor
Forum Pharmaceuticals, Inc.
Condition
Schizophrenia
Drug study icon
CompletedEUCTR 2008-006738-85

A Single Dose, Open-Label, Randomized, Two-Way Crossover Food Effect Study Comparing 12.5 mg FazaClo™ (clozapine) ODT under Fasted and Fed Conditions in Healthy Male Volunteers.

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In United Kingdom
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrug
Countries
United Kingdom
Sponsor
Azur Pharma, Ltd.
Condition
Schizophrenia
Drug study icon
CompletedEUCTR 2019-000063-24

A Study to Evaluate the Safety, Tolerability, and Effect of Risperidone Extended-Release Injectable Suspension (TV-46000) for Subcutaneous Use as Maintenance Treatment in Adult and Adolescent Patie...

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In Bulgaria
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrug
Countries
France, Bulgaria
Sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Condition
Schizophrenia
Data coverage

Public registry coverage is progressing

HopeStage gathers information about mental health clinical trials from the public registries we currently index. We are progressively improving registry coverage, but this does not mean that every study in the world is already included.